Jan Bogaerts

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations

Medicine, Oncology, Treatment Planning +14

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer

Fátima Cardoso, Laura J. van’t Veer, Jan Bogaerts et al. · New England Journal of Medicine · 2016 · 2.1K citations · Full text

Medicine, Genetics, Oncology +16

RECIST 1.1—Update and clarification: From the RECIST committee

Lawrence H. Schwartz, Saskia Litière, Elisabeth G.E. de Vries et al. · European Journal of Cancer · 2016 · 1.9K citations

Agriculture, Public Policy, Separation Of Powers +3

Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial

Mila Donker, Geertjan van Tienhoven, Marieke E. Straver et al. · The Lancet Oncology · 2014 · 1.8K citations · Full text

Medicine, Oncology, Radiation Oncology +17

Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast Cancer

Marc Buyse, Sherene Loi, Laura van’t Veer et al. · JNCI Journal of the National Cancer Institute · 2006 · 1.2K citations · Full text

Medicine, Bioinformatics, Oncology +14